Literature DB >> 22478776

Industry meeting demands for more effective vaccines.

John Carroll.   

Abstract

Swine flu aside, infectious disease is big business. Not all biopharma work is focused on rare diseases; new adjuvants and higher doses may be the answer to better flu control.

Entities:  

Year:  2009        PMID： 22478776      PMCID： PMC2799087     

Source DB:  PubMed          Journal:  Biotechnol Healthc        ISSN： 1554-169X


  2 in total

1.  Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects.

Authors:  Robert B Couch; Patricia Winokur; Rebecca Brady; Robert Belshe; Wilbur H Chen; Thomas R Cate; Bryndis Sigurdardottir; Amy Hoeper; Irene L Graham; Robert Edelman; Fenhua He; Diane Nino; Jose Capellan; Frederick L Ruben
Journal:  Vaccine       Date:  2007-09-14       Impact factor: 3.641

2.  Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.

Authors:  Iain Stephenson; Karl G Nicholson; Katja Hoschler; Maria C Zambon; Kathy Hancock; Joshua DeVos; Jacqueline M Katz; Michaela Praus; Angelika Banzhoff
Journal:  N Engl J Med       Date:  2008-10-09       Impact factor: 91.245
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.